Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Toyoshima (Hamamatsu, Japan), K. Koda (Hamamatsu, Japan), T. Nozue (Hamamatsu, Japan), T. Suda (Hamamatsu, Japan). Benralizumab for severe asthma associated with extra-airway eosinophilic diseases. 2222

Member's Comments

No comment yet.

Related content which might interest you: Late-onset persistent eosinophilic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Clinical outcome of eosinophilic airway inflammation in chronic airway diseases including nonasthmatic eosinophilic bronchitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Bronchiectasis and aspergillus-associated diseases in severe asthma Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Eosinophilic refractory inflammation in OCS-dependent severe asthma Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Mast cells are associated with exacerbations and eosinophilia in children with severe asthma Source: Eur Respir J 2016; 48: 1320-1328 Year: 2016 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Parameters associated with persistent airflow obstruction in chronic severe asthma Source: Eur Respir J 2004; 24: 122-128 Year: 2004 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Factors driving airway eosinophilia in prednisone-dependent severe asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 Bronchiectasis and airway eosinophilia in severe asthma—is there an association? Source: Virtual Congress 2020 – Phenotypes of obstructive diseases Year: 2020 Neutrophilic inflammation in severe asthmatics and COPD patients with the same severity of airway obstruction Source: Eur Respir J 2002; 20: Suppl. 38, 505s Year: 2002 Eosinophilic airway inflammation in COPD and asthma Source: Annual Congress 2008 - Invasive and noninvasive measurements of lung inflammation Year: 2008 Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? Source: Eur Respir J 2003; 22: 8-13 Year: 2003 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Early-onset allergic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Localization of respiratory viral antigens in patients with exacerbations of non allergic late-onset asthma and chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 411s Year: 2004 Prevalence of nasal symptoms and their relation to self-reported asthma and chronic bronchitis/emphysema Source: Eur Respir J 2001; 17: 596-603 Year: 2001 Mepolizumab improves small airway function in severe eosinophilic asthma Source: International Congress 2018 – The value of lung function testing in various pathophysiological conditions Year: 2018 The importance of eosinophilic inflammation in COPD exacerbations Source: International Congress 2017 – COPD management Year: 2017